Merck Rises 13% in a Week: Should You Buy, Sell or Hold the Stock?

Key Takeaways MRK shares jumped nearly 13% as Pfizer's drug-pricing deal lifted sentiment across big pharma.Keytruda drives over half of MRK's pharma sales, but exclusivity ends in 2028.Weak Gardasil demand in China and rising competition weigh on MRK's near-term outlook.Merck’s (MRK) shares have risen almost 13% in the past week as Pfizer’s (PFE) landmark deal with the Trump administration to lower drug costs eased investor concerns over pricing and tariffs in the pharma sector, pushing up stock prices of ...